EGFR and lung carcinoma: Interestingly, we found that high expression levels of EGFR/MAP2K1/mTOR/TEAD1/YAP1 in lung cancer significantly decreased overall levels of active cytotoxic lymphocytes (Figure 5E), mediated dysfunctional T-cell phenotypes, and produced worse overall survival rates of lung cancer cohorts (Figure 5F).